The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Mikhail V. Blagosklonny

Brander Cancer Research Institute

New York Medical College

Hawthorne

New York 10532

USA

[email]@nymc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Brander Cancer Research Institute, New York Medical College, Hawthorne, New York 10532, USA. 2002 - 2004
  • Department of Medicine, New York Medical College, Brander Cancer Research Institute, Hawthorne 10532, USA. 2002 - 2003
  • New York Medical College, 19 Bradhurst Avenue, Suite 2400, Hawthorne, USA. 2003
  • Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. 2002

References

  1. Do cells need CDK2 and ... Bcr-Abl?. Blagosklonny, M.V. Cell Death Differ. (2004) [Pubmed]
  2. Antiangiogenic therapy and tumor progression. Blagosklonny, M.V. Cancer. Cell (2004) [Pubmed]
  3. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers. Blagosklonny, M.V. Cancer Biol. Ther. (2004) [Pubmed]
  4. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Blagosklonny, M.V. Cell. Cycle (2004) [Pubmed]
  5. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Blagosklonny, M.V. Cell. Cycle (2004) [Pubmed]
  6. A new science-business paradigm in anticancer drug development. Blagosklonny, M.V. Trends Biotechnol. (2003) [Pubmed]
  7. Apoptosis, proliferation, differentiation: in search of the order. Blagosklonny, M.V. Semin. Cancer Biol. (2003) [Pubmed]
  8. Cell senescence and hypermitogenic arrest. Blagosklonny, M.V. EMBO Rep. (2003) [Pubmed]
  9. Conceptual research and phenomenology--harmonizing slices. Blagosklonny, M.V. Cell. Cycle (2003) [Pubmed]
  10. Why Iressa failed: toward novel use of kinase inhibitors (outlook). Blagosklonny, M.V., Darzynkiewicz, Z. Cancer Biol. Ther. (2003) [Pubmed]
  11. Cell immortality and hallmarks of cancer. Blagosklonny, M.V. Cell. Cycle (2003) [Pubmed]
  12. Targeting cancer cells by exploiting their resistance. Blagosklonny, M.V. Trends. Mol. Med (2003) [Pubmed]
  13. Matching targets for selective cancer therapy. Blagosklonny, M.V. Drug Discov. Today (2003) [Pubmed]
  14. Oncogenic resistance to growth-limiting conditions. Blagosklonny, M.V. Nat. Rev. Cancer (2002) [Pubmed]
  15. Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Blagosklonny, M.V., Robey, R., Sheikh, M.S., Fojo, T. Cancer Biol. Ther. (2002) [Pubmed]
  16. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Blagosklonny, M.V. Oncogene (2002) [Pubmed]
  17. Combining phorbol ester (PMA) with UCN-01: fueling fire with water. Blagosklonny, M.V., Conney, A.H. Cell. Cycle (2002) [Pubmed]
  18. Four birds with one stone: RAPA as potential anticancer therapy. Blagosklonny, M.V., Darzynkiewicz, Z. Cancer Biol. Ther. (2002) [Pubmed]
  19. Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Blagosklonny, M.V., Darzynkiewicz, Z., Figg, W.D. Cancer Biol. Ther. (2002) [Pubmed]
  20. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Blagosklonny, M.V., Robey, R., Sackett, D.L., Du, L., Traganos, F., Darzynkiewicz, Z., Fojo, T., Bates, S.E. Mol. Cancer Ther. (2002) [Pubmed]
  21. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Blagosklonny, M.V., Darzynkiewicz, Z. Cell. Cycle (2002) [Pubmed]
  22. Are p27 and p21 cytoplasmic oncoproteins?. Blagosklonny, M.V. Cell. Cycle (2002) [Pubmed]
  23. From the war on cancer to translational oncology. Blagosklonny, M.V. Cancer Biol. Ther. (2002) [Pubmed]
 
WikiGenes - Universities